

ChemComm

Chemical Communications

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: J. P. Smalley, G. E. Adams, C. J. Millard, Y. Song, J. K.S. Norris, J. W.R. Schwabe, S. Cowley and J. T. Hodgkinson, *Chem. Commun.*, 2020, DOI: 10.1039/D0CC01485K.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.

COMMUNICATION

PROTAC-Mediated Degradation of Class I Histone Deacetylase Enzymes in Corepressor Complexes

Received 00th January 20xx,
Accepted 00th January 20xxJoshua P. Smalley,^a Grace E. Adams,^b Christopher J. Millard,^c Yun Song,^c James K.S. Norris,^a John W.R. Schwabe,^{*c} Shaun M. Cowley^{*b} and James T. Hodgkinson^{*a}

DOI: 10.1039/x0xx00000x

We have identified a proteolysis targeting chimera (PROTAC) of class I HDACs 1, 2 and 3. The most active degrader consists of a benzamide HDAC inhibitor, an alkyl linker, and the von Hippel-Lindau E3 ligand. Our PROTAC increased histone acetylation levels and compromised colon cancer HCT116 cell viability, establishing a degradation strategy as an alternative to class I HDAC inhibition.

Targeting enzymes involved in the regulation of epigenetic modifications have provided therapeutic drugs in treating cancer and have potential in treating other diseases including neurological disorders and cardiovascular disease.¹ The Histone Deacetylase (HDAC) family of enzymes, often termed epigenetic erasers, function by removing the acetyl moiety from histone tails thereby modifying chromatin structure and gene expression.² Currently five HDAC inhibitors have been approved for clinical use to treat T-cell lymphoma and multiple myeloma with other compounds in clinical trials.³ 18 HDAC enzymes have been identified in humans, 11 with a divalent zinc cation in the catalytic site and 7 sirtuins whose activity is NAD⁺ dependent.⁴ Inhibitors of the Zn²⁺-dependent enzymes, such as Valproic acid or SAHA (Zolinza), are currently used in the clinic to treat cutaneous T-cell lymphoma (CTCL) and bipolar disorder. However, these drugs exhibit limited selectivity and this has been attributed as a cause of their debilitating side-effects in patients.⁵

HDAC 1, 2 and 3 are localized in the nucleus, constitute approximately 50% of total cellular deacetylase activity and are the most prominent HDACs in gene expression.⁶ They do not




Figure 1. Benzamide based HDAC inhibitors. CI-994 demonstrates selective inhibition for HDAC 1, 2 & 3, inhibits cell proliferation, induces apoptosis and has anti-tumor activity. MS-275 is a HDAC 1 & 3 selective inhibitor with anti-tumor activity currently in phase III clinical trials. MGCD0103 is a HDAC 1, 2, 3 inhibitor in clinical trials.

function as singular entities, but exist *in vivo* as catalytic subunits in much larger multi-protein corepressor complexes, including Sin3, NuRD, CoREST, MiDAC and NCoR.⁴ These complexes play an essential role in targeting the HDAC enzyme to specific regions in the genome and demonstrate distinct cell type specific functions.⁷

The Proteolysis Targeting Chimera (PROTAC) technology has been receiving considerable attention as a novel strategy to target difficult-to-drug proteins of interest (POI). PROTACs are heterobifunctional molecules that couple a ligand for the POI with a ligand for an E3 ligase such that the POI becomes polyubiquitinated and degraded by the proteasome.⁸ One of the exciting observations regarding PROTACs is their ability to induce selectivity that has otherwise proved very challenging.⁹ One hypothesis for PROTAC-induced selectivity is the necessity of a protein-protein interaction between the POI and the E3 ligase required for degradation.¹⁰ Towards this endeavor we wanted to generate PROTACs specifically for class I HDAC 1, 2 & 3, present in corepressor complexes.

For our PROTAC design we chose benzamide-based HDAC inhibitors that demonstrate selectivity for HDAC 1, 2 & 3. CI-994 has reported *K_i* values of 0.41 μM for HDAC 1, 0.75 μM for HDAC 3, and approximately 100 μM for HDAC 8 (Fig 1).¹¹ This inhibitor

^a Leicester Institute of Structural and Chemical Biology and Department of Chemistry, University of Leicester, University Road, Leicester, LE1 7RH, UK, E-mail: JTHodgkinson@le.ac.uk

^b Address here. Department of Molecular and Cell Biology, University of Leicester, Leicester LE1 9HN, UK, E-mail: smc57@leicester.ac.uk

^c Leicester Institute of Structural and Chemical Biology and Department of Molecular and Cell Biology, University of Leicester, Leicester LE1 9HN, UK, E-mail: john.schwabe@le.ac.uk

[†] Dr Y. Song present address: Diamond Light Source Ltd, Oxfordshire, OX11 0DE, UK Electronic Supplementary Information (ESI) available: [Full protocols, assays and ¹H and ¹³C NMR data]. See DOI: 10.1039/x0xx00000x




Figure 2. The benzamide acetyl group is surface exposed in a crystal structure bound to the HDAC 2 catalytic active site (PDB: 4LY1). Four preliminary heterobifunctional molecules were synthesised. PROTAC **1** and **3** with a six carbon alkyl linker and either the VHL or Cereblon E3 ligand. PROTAC **2** and **4** with a twelve carbon alkyl linker and either the VHL or Cereblon E3 ligand.


exhibits phenotypes related to HDAC 1, 2 & 3 activity, inhibition of cell proliferation, induction of apoptosis and broad anti-tumor activity *in vitro* and *in vivo*.^{11,12} CI-994 has been in clinical trials for its anti-tumor properties and analogous benzamides, MS-275 and MGCD0103, are currently in phase III clinical trials for breast cancer and non-small cell lung cancer (Fig 1).³ More recently CI-994 has also been reported for its neuroprotective effects in mice following spinal cord injury, the treatment of cognitive disorders, and reducing atrial fibrillation.¹³

We functionalized CI-994 from the acetyl group of the phenyl moiety (Fig 2, see supplementary information for complete synthesis) as the acetyl group of an analogous benzamide inhibitor is protruding from the catalytic active site and surface exposed in a crystal structure bound to HDAC 2.¹⁴ Hence, functionalization at this position should maintain HDAC binding. A short alkyl linker length was prepared (six carbon) and a longer linker length prepared (twelve carbon) as in previous PROTAC studies it has been shown the linker length can play an essential role in inducing degradation.¹⁵ Alkyl linkers were chosen to hasten synthesis. Two different E3 ligands were also chosen; the von Hippel-Lindau (VHL) ligand and the cereblon ligand, since successful protein-protein engagement with an E3 ligase is a critical step in promoting degradation.¹⁰

We evaluated compounds **1-4** *in vitro* using an established fluorescent deacetylase assay with a purified ternary LSD1-CoREST-HDAC1 complex.¹⁶ This complex was used as an exemplar of an HDAC multi-protein complex to help determine if heterobifunctional molecules can still engage with the HDAC enzyme when incorporated into a multi-protein entity. The IC₅₀

values of **1-4** were determined side-by-side with CI-994 as a positive control. As a negative control we also synthesized Boc protected CI-994, compound **5**. Compound **5** is not capable of chelating zinc in the HDAC active site and should be incapable of HDAC inhibition. We observed that CI-994 had an IC₅₀ value of approx. 0.5 μ M consistent with previous reported values,¹¹ and **5** demonstrated no HDAC inhibition (Fig 3A). The putative PROTACs **1** and **3** with shorter linker lengths all engaged HDAC1 in the CoREST complex with IC₅₀ values directly comparable to CI-994, while the longer linker lengths, **2** and **4**, still maintained inhibition but at reduced levels compared to CI-994 and compounds **1** and **3** (Fig 3A). We proceeded to assess the effects of these compounds on HDAC activity in cells. In a previous study we demonstrated that acetylated Histone 3 Lysine 56 (H3K56Ac) is a direct substrate of HDAC 1 in embryonic stem (ES) cells.¹⁷ To examine the ability of **1-4** to reduce HDAC 1 and 2 activity we began by measuring H3K56 acetylation using quantitative western blotting in ES cells (Fig 3B). CI-994 and the pan-HDAC inhibitor, Panobinostat, were used as positive controls and H3K56 acetylation increased as expected, 15-20 fold compared to non-treated cells (Fig 3B). Intriguingly, only the compounds **2** and **4** with longer linker lengths, which were less potent *in vitro* inhibitors against the CoREST complex, caused an increase in histone acetylation (Fig 3B), with **4** resulting in a 10 fold increase at 10 μ M (see supporting info Fig S2).

Figure 3. A) AMC-fluorescence histone deacetylase inhibition assay with the LSD1-CoREST-HDAC complex *in vitro*. B) Histone 3 Lysine 56 acetylation (H3K56Ac) levels in E14 mouse embryonic stem cells after 24h; Negative = untreated, CI-994 = 40 μ M, Panobinostat = 30 nM (For fold change in acetylation levels see supplementary info).



With confirmation that **2** and **4** decrease HDAC activity both *in vitro* and in cells, we proceeded to quantify HDAC 1, 2 & 3 protein abundance. In ES cells approx. 50% degradation was observed, however, degradation was even more prominent in human colon cancer cell line HCT116. After a 24 hour treatment degradation was observed in a dose-dependent manner with **4** in HCT116 (Fig 4A). PROTAC **4**, VHL-based, was a more effective degrader than the cereblon-based PROTAC **2** (see supplementary info Fig S5). HDAC 1 & 2 underwent near complete degradation at 10 μ M with **4**, while HDAC 3 levels were also decreased, but to a lesser extent. At 1 μ M of **4** approximately 50% degradation was observed for HDAC 1, 2 & 3, whilst even at 10 nM of **4** HDAC 1 & 2 levels were still reduced below that of controls. Levels of Histone 3 Lysine 9 acetylation (H3K9Ac), another established residue for HDAC activity,¹⁸ were also determined in HCT116 cells after a 24 hour treatment with **4**. At 10 μ M of **4** acetylation levels were highly elevated compared to the DMSO control (Fig 4B), consistent with decreased HDAC 1, 2 & 3 levels at this concentration (Fig 4A).

Figure 4. HDAC 1, 2 & 3 degradation occurs in a dose dependent manner with **4**. A) Western blot showing protein levels of HDAC1, 2 & 3 and α -tubulin in HCT116 cells following 24 hours of the indicated treatments. Numerical values represent percentage of protein compared to DMSO control = 100% B) Histone H3 Lys9 acetylation levels in HCT116 cells following 24 hours of the indicated treatment. C) The inactive diastereoisomer VHL ligand in **6** does not induce degradation. CI-994 = 40 μ M, Panobinostat = 30 nM





Figure 5. Flow cytometry was used to determine the viability of HCT116 cells following treatment with compound **4** and CI-994 for the indicated times and concentrations. Error bars represent standard deviation of n=3 biological replicates

To confirm HDAC degradation was occurring via a VHL mediated proteasome degradation pathway we synthesised **6** with the inactive diastereoisomer VHL ligand (Fig 4C). No degradation of HDAC 1 & 2 was observed with **6** when compared side-by-side with PROTAC **4** confirming degradation is occurring via a VHL-mediated E3-ubiquitin ligase pathway.

As the most effective of our four PROTAC compounds, we tested the effects of **4** on cell cycle and cell viability of HCT116 cell lines using flow cytometry. After a 48 hour treatment we observed significant cell death at 10 μ M of **4** (Fig 5). At 40 μ M cell death after 48 hours was at similar levels to CI-994 (78% vs 73% respectively). Although the effect of **4** on cell viability was comparable to CI-994 it is important to note that the IC₅₀ of **4** against the LSD1-CoREST-HDAC1 complex *in vitro* was 16.8 μ M compared to 0.5 μ M for CI-994 (Fig 3A), with near complete HDAC 1, 2 & 3 degradation being observed with **4** in this cell line at 10 μ M. Hence, the effects of **4** at 10 μ M are most likely due to the absence of HDAC 1, 2 & 3 by a degradation mechanism rather than enzyme inhibition.

The PROTAC approach has been applied to a number of protein targets, yet, importantly, not all proteins are as amenable to degradation. This has been observed with PROTACs based on non-selective pan-kinase inhibitors.¹⁹ Non-complex forming, cytoplasmic localized HDAC 6 has also recently been identified as a preferential target for degradation with hydroxamic acid based PROTACs.²⁰ In this study, with the synthesis of four heterobifunctional molecules, we have demonstrated the feasibility of targeted degradation of HDAC 1, 2 & 3. These enzymes are localized in the nucleus and present in large multi-protein corepressor complexes. PROTAC **4** produces near complete degradation of HDAC 1, 2 & 3, with an associated increase in global acetylation levels and a loss of cell viability in colon cancer cells. Compounds **1** and **3** despite being a lower molecular weight and more potent HDAC inhibitors *in vitro* than


2 and **4** against the CoREST complex, failed to alter histone acetylation levels in cells by inhibition or degradation. It is tempting to speculate that the increased hydrophobicity of PROTACs **2** and **4** enhances their cell permeability or nucleus localisation in cells. This may account for the discrepancy in HDAC activities in vitro compared to in cells between **1** & **3** and PROTACs **2** & **4**. It seems likely that the linker length and physiochemical properties of Class I HDAC PROTAC linkers will have a profound effect on their activity in cells. Class I HDAC degraders, such as reported in this manuscript, offer an important alternative strategy to inhibition in targeting HDAC corepressor complexes. Such degraders have potential in the development of novel therapeutics in cancer and other diseases related to Class I HDACs.

Conflicts of interest

There are no conflicts to declare.

References

- K.J. Falkenberg, R.W. Johnstone, *Nat Rev Drug Discov.* 2014, **13**, 673; A. Ganesan, P.B. Arimondo, M.G. Rots, C. Jeronimo, M. Berdasco, *Clin. Epigenetics.* 2019, **11**, 174.
- E. Seto, M. Yoshida, *Cold Spring Harb Perspect Biol.* 2014, **6**, a018713; K. R. Stengel, S.W. Hiebert, *Antioxid. Redox. Signal.* 2015, **23**, 51.
- S.Yoon, G.H. Eom, *Chonnam. Med. J.* 2016, **52**, 1.
- C.J. Millard, P.J. Watson, L. Fairall, J.W.R. Schwabe, *Trends. Pharmacol. Sci.* 2017, **38**, 363.
- M. Guha, *Nat. Rev. Drug. Discov.* 2015, **14**, 225.
- S. Jamaladdin, R.D.W. Kelly, L. O'Regan, O.M. Dovey, G.E. Hodson, C.J. Millard, N. Portolano, A.M. Fry, J.W.R. Schwabe, S.M. Cowley, *Proc. Natl. Acad. Sci. U.S.A.* 2014, **111**, 9840; W. Weichert, *Cancer. Lett.* 2009, **280**, 168.
- T. Hayakawa, J. Nakayama, *J Biomed Biotechnol.* 2011, **2011**, 129383 b) R.D. Kelly, S.M. Cowley, *Biochem. Soc. Trans.* 2013, **41**, 741.
- M. Pettersson, C.M. Crews, *Drug Discov Today Technol.* 2019, **31**, 15; S.J. Hughes, A. Ciulli, *Essays Biochem.* 2017, **61**, 505; G.M. Burslem, C.M. Crews, *Cell.* 2020, in press.
- M. Zengerle, K-H Chan, A. Ciulli, *ACS Chem. Biol.* 2015, **10**, 81770.
- M.S. Gadd, A. Testa, X. Lucas, K.H. Chan, W. Chen, D.J. Lamont, M. Zengerle, A. Ciulli, *Nat. Chem. Biol.* 2017, **13**, 514; B.E. Smith, S.L. Wang, S. Jaime-Figueroa, A. Harbin, J. Wang, B.D. Hamman, C.M. Crews, *Nat. Commun.* 2019, **10**, 131.
- T. Beckers, C. Burkhardt, H. Wieland, P. Gimmich, T. Ciossek, T. Maier, K. Sanders, *Int. J. Cancer.* 2007, **121**, 1138.
- P.M. Lorusso, L. Demchik, B. Foster, J. Knight, M.C. Bissery, L.M. Polin, W.R. Leopold, T.H. Corbett, *Invest. New. Drug,* 1996, **14**, 349.
- S. Zhang, Y. Fujita, R. Matsuzaki, T. Yamashita, *Cell Death Dis.* 2018, **9**, 460; J. Gräff, N.F. Joseph, M.E. Horn, A. Samiei, J. Meng, J. Seo, D. Rei, A.W. Bero, T.X. Phan, F. Wagner, E. Holson, J. Xu, J. Sun, R.L. Neve, R.H. Mach, S.J. Haggarty, L-H. Tsai, *Cell*, 2014, **156**, 261. M. Seki, R. LaCanna, J. C. Powers, C. Vrakas, F. Liu, R. Berretta, G. Chacko, J. Holten, P. Jadia, T. Wang, J.S. Arkles, J.M. Copper, S.R. Houser, J. Huang, V.V. Patel, F. A. Recchia, *J. Pharmacol. Exp. Ther.* 2016, **358**, 441.
- B.E. L. Lauffer, R. Mintzer, R. Fong, S. Mukund, C. Tam, I. Zilberleyb, B. Flicke, A. Ritscher, G. Fedorowicz, B. Vallerio, D.F. Ortwine, J. Gunzner, Z. Modrusan, L. Neumann, C.M. Koth, P.J. Lupardus, J.S. Kaminker, C.E. Heise, P. Steiner, *J. Biol. Chem.* 2013, **288**, 26926.
- A.C. Lai, M. Toure, D. Hellerschmied, J. Salami, S. Jamie-Figueroa, E. Ko, J. Hines, C.M. Crews, *Angew. Chem. Int. Ed.* 2016, **55**, 807; K. Cyrus, M. Wehenkel, E.Y. Choi, H.J. Han, H. Lee, H. Swanson, K.B. Kim, *Mol. Biosyst.* 2011, **7**, 359.
- Y. Song, I. Dagil, L. Fairall, N. Robertson, M. Wu, T.J. Ragan, C. Savva, A. Saleh, N. Morone, M.B.A. Kunze, A.G. Jamieson, P.A. Cole, D.F. Hansen, J.W.R. Schwabe, *Cell rep.* 2020, in press.
- O.M. Dovey, C.T. Foster, S.M. Cowley, *Proc. Natl. Acad. Sci. U.S.A.* 2010, **107**, 8242.
- Q. Lai, W. Du, J. Wu, X. Wang, X. Li, X. Qu, X. Wu, F. Dong, R. Yao, H. Fan, *Front. Mol. Neurosci.* 2017, **10**, 376.
- D.P. Bondeson, B.E. Smith, G.M. Burslem, A.D. Buhimschi, J. Hines, S. Jamie-Figueroa, J. Wang, B.D. Hamman, A. Ishchenko, C.M. Crews, *Cell. Chem. Biol.* 2018, **25**, 78.
- Z. An, W. Lv, S. Su, W. Wu, Y. Rao, *Protein Cell.* 2019, **10**, 606; H. Wu, K. Yang, Z. Zhang, E.D. Leisten, Z. Li, H. Xie, J. Liu, K.A. Smith, Z. Novakova, C. Barinka, W. Tang, *J. Med. Chem.* 2019, **62**, 7042.



A heterobifunctional class I HDAC degrader

76x28mm (150 x 150 DPI)